Please login to the form below

Not currently logged in
Email:
Password:

Fabrazyme

This page shows the latest Fabrazyme news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Orchard Therapeutics raises 150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval

Daily Brief: Orchard Therapeutics raises 150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval

Gene therapy trend grows, new rival for Fabrazyme. Orchard Therapeutics raises $150m to advance gene therapy pipeline. ... Galafold (migalastat) will be the first new Fabry treatment on the US market in more than 15 years, and will compete with

Latest news

  • Amicus Therapeutics launches Fabry treatment Galafold in Italy Amicus Therapeutics launches Fabry treatment Galafold in Italy

    Galafold is the first orally administered alternative to the current crop of injectable enzyme replacement therapies (ERT) for Fabry disease, such as Sanofi's Fabrazyme (agalsidase beta).

  • Amicus gets NICE green light for Fabry drug Amicus gets NICE green light for Fabry drug

    Galafold is the first orally administered alternative to the current crop of injectable enzyme replacement therapies (ERT) for Fabry disease, such as Sanofi's Fabrazyme (agalsidase beta) and Shire's Replagal

  • NICE backs Amicus Therapeutics’ Galafold NICE backs Amicus Therapeutics’ Galafold

    Despite initial uncertainty over its clinical effectiveness, the cost-effectiveness watchdog concluded that Galafold provides enough similar benefits to current enzyme replacement therapies (ERT), such as Sanofi's Fabrazyme (agalsidase beta)

  • GSK gene therapy tops CHMP recommendations GSK gene therapy tops CHMP recommendations

    The drug could offer a patient-friendly alternative to injectable Fabry therapies such as Sanofi/Genzyme's Fabrazyme (agalsidase beta) and Shire's Replagal (agalsidase alfa).

  • Sanofi rare disease drug a breakthrough, says FDA Sanofi rare disease drug a breakthrough, says FDA

    Genzyme has built the core of its business by focusing on this group, developing big-selling brands such as Gaucher therapy Cerezyme (imiglucerase alfa), Fabrazyme (agalsidase beta) for Fabry disease and

More from news
Approximately 3 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics